PARIS - Days after announcing that it was to receive an initial milestone payment of €10 million from the Basel, Switzerland-based pharmaceutical company F. Hoffmann-La Roche Ltd., before the end of June, and two months after an up-front payment of €13 million, Transgene SA announced the launch of a €75.7 million (US$101.1 million) capital increase to accelerate the development of its product pipeline and upgrade its manufacturing capabilities. (BioWorld International)

Par Pharmaceutical Cos. Inc. gained exclusive rights in the U.S. to a Phase III drug from Immtech Pharmaceuticals Inc. for treating pneumocystis pneumonia in AIDS patients. (BioWorld Today)